<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id>
<journal-id journal-id-type="hwp">jbc</journal-id>
<journal-id journal-id-type="pmc">jbc</journal-id>
<journal-id journal-id-type="publisher-id">JBC</journal-id>
<journal-title-group>
<journal-title>The Journal of Biological Chemistry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9258</issn>
<issn pub-type="epub">1083-351X</issn>
<publisher>
<publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
<publisher-loc>11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110, U.S.A.</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30257870</article-id>
<article-id pub-id-type="pmc">6254356</article-id>
<article-id pub-id-type="publisher-id">RA118.004653</article-id>
<article-id pub-id-type="doi">10.1074/jbc.RA118.004653</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editors' Picks</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Angelman syndrome–associated point mutations in the Zn<sup>2+</sup>-binding N-terminal (AZUL) domain of UBE3A ubiquitin ligase inhibit binding to the proteasome</article-title>
<alt-title alt-title-type="short">Characterizing the interaction of UBE3A/E6AP with PSMD4</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kühnle</surname>
<given-names>Simone</given-names>
</name>
<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/content/293/47/18387/suppl/DCAuthor_profile"></ext-link>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martínez-Noël</surname>
<given-names>Gustavo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leclere</surname>
<given-names>Flavien</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hayes</surname>
<given-names>Sebastian D.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>§</sup>
</xref>
<xref ref-type="author-notes" rid="FN1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harper</surname>
<given-names>J. Wade</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>§</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-8668-9579</contrib-id>
<name>
<surname>Howley</surname>
<given-names>Peter M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>‡</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>2</sup>
</xref>
</contrib>
<aff id="aff1">From the Departments of <label>‡</label>Microbiology and Immunobiology and </aff>
<aff id="aff2"><label>§</label>Cell Biology, Harvard Medical School, Boston, Massachusetts 02115</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>2</label> To whom correspondence should be addressed:
<addr-line>Dept. of Microbiology and Immunobiology, Harvard Medical School, NRB, Rm. 950, 77 Ave. Louis Pasteur, Boston, MA 02115.</addr-line> Tel.:
<phone>617-432-2889</phone>; Fax:
<fax>617-432-2882</fax>; E-mail:
<email>peter_howley@hms.harvard.edu</email>.</corresp>
<fn fn-type="present-address" id="FN1">
<label>1</label>
<p>Present address: Agios Pharmaceuticals, 88 Sidney St., Cambridge, MA, 02139.</p>
</fn>
<fn fn-type="edited-by">
<p>Edited by George N. DeMartino</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>23</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>26</day>
<month>9</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>293</volume>
<issue>47</issue>
<fpage>18387</fpage>
<lpage>18399</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>16</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 Kühnle et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Kühnle et al.</copyright-holder>
<license>
<license-p>Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="zbc04718018387.pdf"></self-uri>
<abstract>
<p>Deregulation of the HECT ubiquitin ligase UBE3A/E6AP has been implicated in Angelman syndrome as well as autism spectrum disorders. We and others have previously identified the 26S proteasome as one of the major UBE3A-interacting protein complexes. Here, we characterize the interaction of UBE3A and the proteasomal subunit PSMD4 (Rpn10/S5a). We map the interaction to the highly conserved Zn<sup>2+</sup>-binding N-terminal (AZUL) domain of UBE3A, the integrity of which is crucial for binding to PSMD4. Interestingly, two Angelman syndrome point mutations that affect the AZUL domain show an impaired ability to bind PSMD4. Although not affecting the ubiquitin ligase or the estrogen receptor α–mediated transcriptional regulation activities, these AZUL domain mutations prevent UBE3A from stimulating the Wnt/β-catenin signaling pathway. Taken together, our data indicate that impaired binding to the 26S proteasome and consequential deregulation of Wnt/β-catenin signaling might contribute to the functional defect of these mutants in Angelman syndrome.</p>
</abstract>
<kwd-group>
<kwd>autism</kwd>
<kwd>proteasome</kwd>
<kwd>estrogen receptor</kwd>
<kwd>Wnt signaling</kwd>
<kwd>E3 ubiquitin ligase</kwd>
<kwd>Angelman syndrome</kwd>
<kwd>AZUL domain</kwd>
<kwd>E6AP</kwd>
<kwd>PSMD4</kwd>
<kwd>UBE3A</kwd>
</kwd-group>
<funding-group>
<award-group id="award1">
<funding-source>
<institution-wrap>
<institution>HHS National Institutes of Health (NIH)
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>R35CA197262</award-id>
<award-id>AG011085</award-id>
</award-group>
<award-group id="award2">
<funding-source>
<institution-wrap>
<institution>Deutsche Forschungsgemeinschaft (DFG)
</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/501100001659</institution-id>
</institution-wrap>
</funding-source>
<award-id>KU 3196/2–1</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>